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emergency cases were young people under 40 years old. Male patients (53.9%) were 
more than female patients. The frequency of emergency visit is 2.7 average per year, 
male patients get 3.0 visits more than female 2.4 visits. About 33.9% of patients 
at one’s own expense. Diseases in the top five were respiratory disease, trauma, 
digestive system diseases, circulation system disease, urinary diseases, respec-
tively. Respiratory disease was the leading member in the spectrum, accounting 
for 25.5%. Poisoning patients account for 1.6% of all emergency cases. Wounded 
patients mostly centralized from May to August, and the bottom periods of the treat-
ment time appeared in midnight (0:00 – 6:00), accounting for 5.5%. CONCLUSIONS: 
Composition of emergency disease spectrum and characteristics of time distribu-
tion can help to develop new prevention and treatment strategies for improving 
quality and increase efficiency. The treatment for respiratory disease headed the 
list of emergency disease spectrum need to optimize medical resourse utilization 
and process improvement.
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OBJECTIVES: To identify the key trends in healthcare spending in Brazil in 
2015. METHODS: Review of the Ministry of Health (for programs), Ministry of 
Planning (for budget) and Workd Bank (for GDP growth) reports as well as recently 
published financial information on Bloomberg and Valor (Brazilian newspaper) on 
Federal and States spending. RESULTS: The economic program established by the 
Brazilian government forecasts growth will return only in 2016. It is worth remem-
bering that in 2014 the GDP growth in Brazil was very close to nil. In 2015, economists 
expect the GDP increase to be below 1%. The Ministry of Health budget in 2014 
was US$ 45.6 billion vs. 2015: US 41.2 billion, a 9.6% reduction caused by increased 
inflation and the devaluation of the Brazilian real against the American dollar. 
Moreover, with the reduction in the price of oil some states, such as Rio de Janeiro, 
might lose US$ 750 million in royalties. In the private setting, ANS, the Federal 
agency that regulates private payers (HMOS, healthcare insurers, etc.), is getting 
ready this year to work on the update of the Minimum Mandatory Coverage List valid 
January 2016 on. In a sector in which 80% of the health plans are either collective 
(unions) or paid by companies, thus, dependent on the expansion of the economy, 
the willingness to pay for the incorporation of new technologies would probably be 
low. CONCLUSIONS: With a struggling economy ahead and consequently smaller 
budgets, not only does the Federal Government foresee adjustments in public 
spending but also do State Governments. Context indicates that dialogue and flex-
ibility among healthcare players will be needed more than ever.
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OBJECTIVES: In 2012, the United States Food and Drug Administration (FDA) created 
a new expedited pathway of “Breakthrough Therapy Designation” (BTD) to enable 
an early approval of therapies which have shown substantial activity in early trials. 
The objective of this study was to assess the comparative effectiveness and pric-
ing of drugs with BTD. METHODS: The data for the number of granted BTDs was 
obtained from FDA.gov. The data for publically disclosed BTDs was obtained from 
sponsor’s press releases. For all products, the information for their mechanism 
of action, type of molecule, trial design, clinical efficacy and safety, and pricing 
and time to approval (for approved products) were obtained from peer-reviewed 
publications, conference abstracts, FDA and sponsor websites. RESULTS: Since the 
establishment of the BTD pathway, 55 products have been granted breakthrough 
therapy designations (2012-2014), of which, 42 have been publically disclosed by the 
manufacturers and 6 have been approved by the FDA. In terms of indications, 43% 
are for cancer, 18% are for genetic diseases and 14% are for Hepatitis C Genotype 
1. The median time to approval for these three drug was ~5 years, significantly 
shorter than the 2012 median time to approval for priority review applications 
(6 years). The price premium was 30-50%, compared to other drugs in the same 
category. The six approved BTDs show 20-30% higher response rates than other 
products in the same category. The other products in the pipeline with established 
comparators show 36%-136% improvement in efficacy (based on active controls or 
previous trials). For approximately half of the products, comparative efficacy can-
not be determined because of no previous evidence for a product with efficacy in 
the targeted indications. CONCLUSIONS: BTD is a promising pathway to shorten 
development time and provides early access, however, the high price could pose 
challenges for payers and patients.
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OBJECTIVES: Demonstrate possible savings by expanding the responsible use of 
OTCs (over-the-counter or nonprescription drugs) in Brazil in the public perspec-
tive. METHODS: Measure the volume and medical costs on public health system 
emergency and usage of OTC medicines. Data were obtained from the DATASUS 
system (030106006), SIGTAP 3.01.1.1.3, and research CHPA / USA January 2012 and 
adopted the premise of 10% OTC in the treatment of common diseases (common 
flu, allergy, and pain), to identify the average ticket cost on OTC consumption were 
used IMS Health of 2013 data and for absenteeism costs were used the Brazilian 
Ministry of work and IBGE data. RESULTS: It was estimated that 8% (5,101,692) of 
all emergency attendances in SUS 2013 resulted in prescriptions that exhibited 
OTC medicines to treat common diseases, at a cost of 56 million,costs related to 
improductible days at BRL 369 million and expenditure in the acquisition of these 
assessment ranking showed that 46.2% of AEs were classified as probable, 35.9% 
possible and 7.9% certain. Based on severity of the AEs, 59.0% were classified as 
moderate 30.8% severe, 5.1% mild and lethal respectively. 87.2% of the AEs were 
assessed as possibly preventable. Assessment of outcomes showed that 94.9% of 
the patients recovered fully while 5.1% died. The organs/systems mostly involved 
in the adverse events were the CNS (headache, dizziness and body pain, 22.1%), 
cutaneous organ (rashes and itching, 19.6%) and respiratory system (Breathlessness 
and cough, 13.5%) Antihypertensives (76.8%), antibiotics (10%), antiretrovirals (7.7%) 
and cholesterol lowering agents (7.7%) were the most commonly implicated classes 
of drugs. CONCLUSIONS: The study shows that AEs constitute a significant cause 
of hospital admissions and a good number will likely develop during hospitaliza-
tion. Intensive monitoring and evaluation of AEs is feasible and will likely provide 
a clearer picture of clinical outcomes.
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OBJECTIVES: Worldwide, the number of disabled individuals is used as a marker for 
population health status because of high morbidity and mortality burden associated 
with disability. Prior studies, which analyzed racial/ethnic disparities in individu-
als with disability, have limitations in regards to population, scope or were limited 
to individuals with chronic condition. The purpose of this study is to determine 
prevalence of disability in different racial/ethnic groups using a standard framework 
for disability. METHODS: A retrospective cross-sectional study design with data 
from 7,993 individuals aged above 21 years from 2012 National Health Interview 
Survey (NHIS) was adopted. Race/ethnicity was categorized into: 1) White; 2) African 
American; 3) Latino and 4) other. Disability was defined based on a standard set 
of questions about mobility, self-care, and cognition from the “Functioning and 
Disability” supplement of 2012 NHIS and it was grouped as: 1) No disability; 2) 
Moderate disability; and 3) Severe disability. Chi-square tests and multinomial logis-
tic regressions were conducted to examine the association between race/ethnicity 
and disability. RESULTS: There were statistically significant racial/ethnic differ-
ences in disability status; 10.2% Whites, 14.8% African Americans, 8.1% Latino, and 
6.7% other racial minorities had severe disability. Without adjustments for socio-
economic status, African Americans were more likely to have severe disability than 
Whites (AOR= 1.56, 95% CI= 1.24, 1.95) and Latinos were less likely to have severe 
disability (AOR = 0.70, 95% CI= 0.55, 0.90). After adjusting for socio-economic status, 
we did not observe statistically significant differences in disability status among 
African Americans and Whites. After adjusting for presence of chronic conditions, 
statistically significant differences in disability status among Latinos and Whites 
disappeared. CONCLUSIONS: Differences in prevalence of disability between 
African Americans and Whites can be partially explained by low socio-economic 
status of African Americans. Improving socio-economic status of African Americans 
may reduce racial disparities in disability prevalence.
PHP98
comParative effectiveness researcH (cer) and its effect on tHe 
HealtH care decision-maKing environment
Westrich K.D.
National Pharmaceutical Council, Washington, DC, USA
OBJECTIVES: Track the perceptions of key CER stakeholders about the current and 
future effects of CER on evidence generation and application for health care deci-
sions METHODS: Internet and mail survey of health care stakeholders, including 
government, health plans, researchers, human resources specialists, employers, and 
trade organizations, that are influential in or affected by CER; telephone follow-up to 
maximize response. RESULTS: Two-thirds of CER stakeholders say that the current 
CER evidence base is insufficient to support treatment decisions, but 90 percent 
remain committed to the importance of CER. This fifth survey in a series begun in 
2010 found fewer respondents reporting no short-term effects of CER, but more than 
half of respondents believe that substantial improvement in decision-making based 
on CER will occur over the next 5 years. Almost three-fourths of respondents recog-
nize PCORI’s significance in funding and monitoring new research, nearly double the 
level five years ago. Respondents are more positive about research priorities; nearly 
40 percent believe priorities somewhat/adequately reflect treatment choices faced 
by patients and providers, compared to only 22 percent two years ago. Just 9 percent 
believe that processes for interpreting evidence are fully transparent and objective, 
fewer than in the previous three surveys. Only about 25% of respondents report that 
real-world evidence or evidence about variability in individual patient response is 
being used to support treatment decisions. CONCLUSIONS: In successive surveys, 
CER stakeholders continue to look to a five-year horizon for significant effects from 
CER. They generally view the evidence base as incomplete, recognize the key players 
in generating new evidence, and understand the time needed for research in their 
projections of CER’s impact. The relatively scarce use of real-world evidence and 
evidence about patient variability reflects their views about the completeness of 
the evidence base to support treatment decisions.
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OBJECTIVES: This study is to analyze age, disease category, time of emergency treat-
ment and regularity of visiting doctors in order to realize the distribution of disease 
spectrum and epidemiological analysis in emergency department in the top three 
hospital in China. METHODS: To select 29,654 cases in emergency department of 
hospital database of 2013. The top five emergency diseases were studied by ret-
rospective research. Data analysis was performed with STATA software package. 
ncy department in the top three hospital in China. RESULTS: The majority of the 
